---
title: "Our History"
title-block-banner: "./img/back1.jpg"
---

## From Academic Innovation to a Clinical-Stage Oral Immunotherapy Platform

Our foundational technology, an oral T-cell immunotherapy platform, was developed at UC San Diego by Dr. Andreas Niethammer [@niethammer_dna_2002]. His vision was to create a safe, convenient, and effective cancer therapy. Today, as VAXIMM's Chief Medical Officer, Dr. Niethammer continues to guide this innovative research from the laboratory to patients in need.

```{=html}
<style>
    /* --- General Styling --- */
    body {
        font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif;
        line-height: 1.6;
        color: #333;
        background-color: #f9f9f9;
        margin: 0;
        padding: 2rem;
    }

    .container {
        max-width: 900px;
        margin: auto;
        background: #fff;
        padding: 2rem;
        border-radius: 12px;
        box-shadow: 0 4px 25px rgba(0, 0, 0, 0.05);
        margin-bottom: 2rem;
    }

    .container > h1 {
        text-align: center;
        color: #003366;
        margin-bottom: 2rem;
    }
    
    .container > h2 {
        color: #003366;
        margin-bottom: 2rem;
    }

    /* --- Interactive Timeline --- */
    .timeline {
        position: relative;
        padding: 2rem 0;
        margin-bottom: 2rem;
    }

    .timeline::before {
        content: '';
        position: absolute;
        top: 0;
        left: 50%;
        transform: translateX(-50%);
        width: 3px;
        height: 100%;
        background-color: #e0e0e0;
    }

    .timeline-item {
        padding: 10px 40px;
        position: relative;
        width: 50%;
        box-sizing: border-box;
    }
    
    /* Position items left and right */
    .timeline-item:nth-child(odd) {
        left: 0;
        text-align: right;
    }

    .timeline-item:nth-child(even) {
        left: 50%;
    }
    
    /* Timeline circle marker */
    .timeline-item::after {
        content: '';
        position: absolute;
        width: 20px;
        height: 20px;
        right: -11px;
        background-color: white;
        border: 4px solid #0056b3;
        top: 25px;
        border-radius: 50%;
        z-index: 1;
    }

    .timeline-item:nth-child(even)::after {
        left: -9px;
    }

    .timeline-content {
        padding: 20px;
        background: #f0f8ff;
        border-radius: 8px;
        cursor: pointer;
        transition: transform 0.3s ease, box-shadow 0.3s ease;
    }
    
    .timeline-content:hover {
        transform: translateY(-5px);
        box-shadow: 0 8px 15px rgba(0, 131, 179, 0.1);
    }

    .timeline-content h3 {
        margin-top: 0;
        color: #0056b3;
        font-size: 1.2rem;
    }

    .timeline-content .description {
        max-height: 0;
        overflow: hidden;
        transition: max-height 0.5s ease-out;
        font-size: 0.95rem;
    }
    
    .timeline-content.active .description {
        max-height: 200px; /* Adjust as needed */
        margin-top: 1rem;
    }

    /* --- Other Sections --- */
    .grid-container {
        display: grid;
        grid-template-columns: 1fr 1fr;
        gap: 2rem;
        margin-top: 3rem;
    }

    .card {
        background: #ffffff;
        padding: 1.5rem;
        border-radius: 8px;
        box-shadow: 0 4px 10px rgba(0,0,0,0.05);
        border: 1px solid #eee;
    }
    
    .card h3 {
        margin-top: 0;
        color: #003366;
        border-bottom: 2px solid #e0e0e0;
        padding-bottom: 0.5rem;
    }
    
    /* Innovator Card */
    .innovator-card {
        text-align: center;
    }
    
    .innovator-card .quote {
        font-style: italic;
        color: #555;
        margin-top: 1rem;
    }
    
    /* Key Facts */
    .key-facts ul {
        list-style: none;
        padding: 0;
    }
    .key-facts li {
        margin-bottom: 0.75rem;
        font-size: 1rem;
    }
    
    /* Partners */
    .partner-logos {
        display: flex;
        justify-content: space-around;
        align-items: center;
        flex-wrap: wrap;
        gap: 1rem;
        padding-top: 1rem;
    }
    .partner-logos img {
        max-height: 40px;
        filter: grayscale(100%);
        transition: filter 0.3s ease;
    }
    .partner-logos img:hover {
        filter: grayscale(0%);
    }

    /* --- Responsive Design --- */
    @media screen and (max-width: 768px) {
        .timeline::before {
            left: 10px;
        }
        .timeline-item {
            width: 100%;
            padding-left: 50px;
            padding-right: 0;
        }
        .timeline-item:nth-child(odd),
        .timeline-item:nth-child(even) {
            left: 0;
            text-align: left;
        }
        .timeline-item::after {
            left: 1px;
        }
        .grid-container {
            grid-template-columns: 1fr;
        }
    }
</style>

<div class="container">
    <h1>Company Milestones</h1>
    
    <div class="timeline">
        <div class="timeline-item">
            <div class="timeline-content" onclick="toggleDescription(this)">
                <h3>2008 - Company Foundation</h3>
                <div class="description">
                    <p>VAXIMM was founded as a spin-out from UC San Diego, based on Dr. Andreas Niethammer's pioneering research into oral T-cell immunotherapy, and joint venture of BB Biotech Ventures and Merck KGaA.</p>
                </div>
            </div>
        </div>
        <div class="timeline-item">
            <div class="timeline-content" onclick="toggleDescription(this)">
                <h3>2011 - First-in-Human Study for VXM01</h3>
                <div class="description">
                    <p>VAXIMM initiated its first clinical trial, a Phase I dose escalation study, for VXM01. The study enrolled pancreatic cancer patients at Heidelberg University Hospital to evaluate the vaccine's safety, tolerability, and immunogenicity.</p>
                </div>
            </div>
        </div>
        <div class="timeline-item">
            <div class="timeline-content" onclick="toggleDescription(this)">
                <h3>2017 - Key Clinical Partnership</h3>
                <div class="description">
                    <p>A key clinical trial was launched to test VAXIMM's lead candidate, VXM01, in combination with the checkpoint inhibitor avelumab.</p>
                </div>
            </div>
        </div>
        <div class="timeline-item">
            <div class="timeline-content" onclick="toggleDescription(this)">
                <h3>2018 - Strategic Licensing Agreement</h3>
                <div class="description">
                    <p>A major licensing deal with China Medical System (CMS) expanded VAXIMM's reach, granting CMS rights to develop and commercialize products in Asia.</p>
                </div>
            </div>
        </div>
        <div class="timeline-item">
            <div class="timeline-content" onclick="toggleDescription(this)">
                <h3>2022 - Acquisition and Growth</h3>
                <div class="description">
                    <p>Acquired by BCM Europe AG, VAXIMM became a key subsidiary of OSR Holdings, Inc. (NASDAQ:OSRH), accelerating its mission to deliver next-gen therapies.</p>
                </div>
            </div>
        </div>
    </div>
</div>

<script>
    // Simple JavaScript to toggle the active class for the timeline description
    function toggleDescription(element) {
        element.classList.toggle('active');
    }
</script>
```

## Team

```{=html}
<!-- Bootstrap CSS -->
<link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/css/bootstrap.min.css" rel="stylesheet">
<!-- Bootstrap Icons -->
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap-icons@1.11.1/font/bootstrap-icons.css">
<style>
    /* Optional: Custom styles for a cleaner look */
    .team-card .card-img-top {
        /* Adjust these values to make the photo smaller */
        width: 120px; /* Increased slightly for better visual balance */
        height: 120px;
        object-fit: cover;
        margin: 1.5rem auto 0 auto; /* Center image and add space */
    }
    .team-card .card-title {
        font-weight: bold;
        text-transform: uppercase;
        font-size: 1.1rem;
        color: #333;
        text-align: center;
    }
    .team-card .card-subtitle {
        text-transform: uppercase;
        font-size: 0.8rem;
        letter-spacing: 1px;
    }
    .team-card {
        transition: transform 0.3s ease, box-shadow 0.3s ease;
    }
    .team-card:hover {
        transform: translateY(-5px);
        box-shadow: 0 8px 25px rgba(0,0,0,0.15) !important;
    }
</style>

<div class="container-xl py-5">
    <div class="row justify-content-center g-4">
        <!-- Card 1 -->
        <div class="col-12 col-md-6 col-lg-6">
            <div class="card text-center border-0 shadow-sm team-card h-100">
                <img src="https://cdn.theorg.com/48250e5d-580b-4e1c-926e-7c31a1178ef5_thumb.jpg" 
                        class="card-img-top rounded-circle" 
                        alt="Dr. Andreas Niethammer"
                        onerror="this.onerror=null;this.src='https://placehold.co/120x120/EFEFEF/AAAAAA?text=Image';">
                <div class="card-body d-flex flex-column">
                    <h5 class="card-title mt-3 text-center">Andreas Niethammer, MD, PhD</h5>
                    <h6 class="card-subtitle mb-3 text-muted">Chief Medical Officer</h6>
                    <p class="card-text text-secondary">
                        As the inventor of VAXIMM's core technology platform at UCSD, Dr. Niethammer provides foundational scientific leadership. He has extensive experience in clinical oncology and immunology and is responsible for guiding the company's clinical development strategy and execution.
                    </p>
                    <div class="mt-auto">
                            <a href="https://www.linkedin.com/in/andreas-niethammer-md-phd-4a086323/" class="text-secondary mx-2 fs-4" aria-label="LinkedIn Profile">
                            <i class="bi bi-linkedin"></i>
                        </a>
                    </div>
                </div>
            </div>
        </div>
        <!-- Card 2 -->
        <div class="col-12 col-md-6 col-lg-6">
            <div class="card text-center border-0 shadow-sm team-card h-100">
                <img src="https://media.licdn.com/dms/image/v2/D4D03AQGB90T0Kskf3g/profile-displayphoto-shrink_200_200/profile-displayphoto-shrink_200_200/0/1726660412965?e=1762992000&v=beta&t=NL14nIc0TzxdBiu1Eiv6aIwWED6fqjdAExB8zqBvl-0" 
                        class="card-img-top rounded-circle" 
                        alt="Sébastien Wieckowski"
                        onerror="this.onerror=null;this.src='https://placehold.co/120x120/EFEFEF/AAAAAA?text=Image';">
                <div class="card-body d-flex flex-column">
                    <h5 class="card-title mt-3 text-center">Sébastien Wieckowski, PhD</h5>
                    <h6 class="card-subtitle mb-3 text-muted">Senior Director Platform Optimization and Nonclinical Development</h6>
                    <p class="card-text text-secondary">
                        Dr. Wieckowski has 15 years experience in oncoimmunology and vaccine development. He joined VAXIMM in 2016 as Senior Scientist, where he was in charge of the preclinical development of the various assets.
                    </p>
                    <div class="mt-auto">
                        <a href="https://linkedin.com/in/sbwiecko" class="text-secondary mx-2 fs-4" aria-label="LinkedIn Profile">
                            <i class="bi bi-linkedin"></i>
                        </a>
                    </div>
                </div>
            </div>
        </div>
    </div>
</div>

<!-- Bootstrap JS Bundle -->
<script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/js/bootstrap.bundle.min.js"></script>
```

## Advisors

```{=html}
<div class="container-xl py-5">
    <div class="row justify-content-center g-4">
        <!-- Card 1 -->
        <div class="col-12 col-md-6 col-lg-6">
            <div class="card text-center border-0 shadow-sm team-card h-100">
                <img src="https://cdn.imweb.me/thumbnail/20250306/1d5ed476437bb.jpeg" 
                        class="card-img-top rounded-circle" 
                        alt="Dr. Andreas Niethammer"
                        onerror="this.onerror=null;this.src='https://placehold.co/120x120/EFEFEF/AAAAAA?text=Image';">
                <div class="card-body d-flex flex-column">
                    <h5 class="card-title mt-3 text-center">Constance Höfer, PhD</h5>
                    <p class="card-text text-secondary">
                        Dr. Höfer is a seasoned biopharma executive with a strong scientific foundation, holding a Ph.D. in Pharmacology from the University of Newcastle. Her career is marked by significant leadership roles, including serving as Global Program Head at both Merck Healthcare and Sandoz Biopharma. She also bring deep operational and development expertise from her time as COO of Priaxon AG and VP of Drug Development at Medigene AG.
                    </p>
                    <div class="mt-auto">
                            <a href="https://www.linkedin.com/in/constance-hoefer/" class="text-secondary mx-2 fs-4" aria-label="LinkedIn Profile">
                            <i class="bi bi-linkedin"></i>
                        </a>
                    </div>
                </div>
            </div>
        </div>
        <!-- Card 2 -->
        <div class="col-12 col-md-6 col-lg-6">
            <div class="card text-center border-0 shadow-sm team-card h-100">
                <img src="https://cdn.imweb.me/thumbnail/20250311/272b019106a04.jpeg" 
                        class="card-img-top rounded-circle" 
                        alt="Sébastien Wieckowski"
                        onerror="this.onerror=null;this.src='https://placehold.co/120x120/EFEFEF/AAAAAA?text=Image';">
                <div class="card-body d-flex flex-column">
                    <h5 class="card-title mt-3 text-center">Josh Pan, PhD</h5>
                    <p class="card-text text-secondary">
                        Dr. Pan provides a dual perspective in science and business, holding both a Ph.D. in Molecular and Cellular Biology and an MBA from the University of Washington. He possesses extensive experience in venture capital and corporate strategy, having served as Partner at Bellevue Capital Management, Chief Operating Officer at the W Fund, Chief Business Officer at Landmark BioVentures, and Vice President of Corporate Development and External Affairs at Athira Pharma.
                    </p>
                    <div class="mt-auto">
                        <a href="https://www.linkedin.com/in/joshpan/" class="text-secondary mx-2 fs-4" aria-label="LinkedIn Profile">
                            <i class="bi bi-linkedin"></i>
                        </a>
                    </div>
                </div>
            </div>
        </div>
    </div>
</div>
```

## OSR Holdings

[**OSR Holdings, Inc.** (NASDAQ:OSRH)](https://osr-holdings.com/company) is a healthcare group that operates on a hub-and-spoke model. The company focuses on partnering with biopharmaceuticals that have innovative R&D platforms. OSR Holdings' current portfolio includes technologies in immuno-oncology, regenerative biologics, and medical devices. They leverage a global network across the US, Europe, and Korea to develop a wide range of healthcare solutions.

## Careers

We are always looking for passionate and talented individuals to help advance our mission. We welcome open applications from professionals with expertise in key areas such as **Regulatory Affairs**, **CMC** (Chemistry, Manufacturing, and Controls), clinical development, and other related fields.

If you are interested in joining VAXIMM, please send your spontaneous application and CV to: <careers@vaximm.com>
